Segment Wealth Management LLC Increases Stock Holdings in Eli Lilly and Company $LLY

Segment Wealth Management LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 225.6% in the 3rd quarter, Holdings Channel reports. The firm owned 14,494 shares of the company’s stock after buying an additional 10,042 shares during the quarter. Segment Wealth Management LLC’s holdings in Eli Lilly and Company were worth $11,059,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth about $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter worth about $29,000. Steph & Co. grew its holdings in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares in the last quarter. Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth approximately $31,000. Finally, Bare Financial Services Inc raised its stake in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LLY. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Scotiabank began coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target on the stock. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Bank of America dropped their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Trading Up 0.1%

Shares of LLY opened at $1,079.84 on Wednesday. The stock has a market capitalization of $1.02 trillion, a P/E ratio of 52.83, a PEG ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a fifty day simple moving average of $997.74 and a two-hundred day simple moving average of $845.33.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the company posted $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.